vs
Side-by-side financial comparison of Foxx Development Holdings Inc. (FOXX) and Gossamer Bio, Inc. (GOSS). Click either name above to swap in a different company.
Foxx Development Holdings Inc. is the larger business by last-quarter revenue ($16.7M vs $13.8M, roughly 1.2× Gossamer Bio, Inc.). Foxx Development Holdings Inc. runs the higher net margin — -25.6% vs -342.3%, a 316.7% gap on every dollar of revenue. On growth, Gossamer Bio, Inc. posted the faster year-over-year revenue change (47.1% vs -4.4%).
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
FOXX vs GOSS — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.7M | $13.8M |
| Net Profit | $-4.3M | $-47.2M |
| Gross Margin | 13.3% | — |
| Operating Margin | -13.3% | -333.6% |
| Net Margin | -25.6% | -342.3% |
| Revenue YoY | -4.4% | 47.1% |
| Net Profit YoY | -400.9% | -43.0% |
| EPS (diluted) | $-0.62 | $-0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.7M | $13.8M | ||
| Q3 25 | $20.2M | $13.3M | ||
| Q2 25 | $13.9M | — | ||
| Q1 25 | $11.4M | — | ||
| Q4 24 | $17.5M | — | ||
| Q3 24 | $23.1M | — | ||
| Q2 24 | — | $95.8M | ||
| Q1 24 | — | $0 |
| Q4 25 | $-4.3M | $-47.2M | ||
| Q3 25 | $-2.9M | $-48.2M | ||
| Q2 25 | $-4.1M | — | ||
| Q1 25 | $-4.1M | — | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $-2.3M | — | ||
| Q2 24 | — | $49.2M | ||
| Q1 24 | — | $-41.9M |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 13.6% | — | ||
| Q2 25 | 10.9% | — | ||
| Q1 25 | 5.8% | — | ||
| Q4 24 | 12.5% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -13.3% | -333.6% | ||
| Q3 25 | -4.4% | -369.4% | ||
| Q2 25 | -15.0% | — | ||
| Q1 25 | -31.3% | — | ||
| Q4 24 | -12.8% | — | ||
| Q3 24 | -7.8% | — | ||
| Q2 24 | — | 54.3% | ||
| Q1 24 | — | — |
| Q4 25 | -25.6% | -342.3% | ||
| Q3 25 | -14.2% | -362.7% | ||
| Q2 25 | -29.4% | — | ||
| Q1 25 | -35.9% | — | ||
| Q4 24 | 8.1% | — | ||
| Q3 24 | -9.8% | — | ||
| Q2 24 | — | 51.4% | ||
| Q1 24 | — | — |
| Q4 25 | $-0.62 | $-0.21 | ||
| Q3 25 | $-0.42 | $-0.21 | ||
| Q2 25 | $-0.44 | — | ||
| Q1 25 | $-0.58 | — | ||
| Q4 24 | $0.20 | — | ||
| Q3 24 | $-0.65 | — | ||
| Q2 24 | — | $0.22 | ||
| Q1 24 | — | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8M | $136.9M |
| Total DebtLower is stronger | $84.8K | — |
| Stockholders' EquityBook value | $-11.8M | $-122.8M |
| Total Assets | $42.0M | $172.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | $136.9M | ||
| Q3 25 | $1.5M | $180.2M | ||
| Q2 25 | $1.9M | — | ||
| Q1 25 | $3.8M | — | ||
| Q4 24 | $3.9M | — | ||
| Q3 24 | $9.2M | — | ||
| Q2 24 | — | $354.5M | ||
| Q1 24 | — | $244.4M |
| Q4 25 | $84.8K | — | ||
| Q3 25 | $90.2K | — | ||
| Q2 25 | $97.2K | — | ||
| Q1 25 | $100.5K | — | ||
| Q4 24 | $105.5K | — | ||
| Q3 24 | $110.3K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-11.8M | $-122.8M | ||
| Q3 25 | $-7.9M | $-82.3M | ||
| Q2 25 | $-5.4M | — | ||
| Q1 25 | $-1.6M | — | ||
| Q4 24 | $2.2M | — | ||
| Q3 24 | $457.2K | — | ||
| Q2 24 | — | $81.5M | ||
| Q1 24 | — | $26.7M |
| Q4 25 | $42.0M | $172.2M | ||
| Q3 25 | $49.8M | $208.8M | ||
| Q2 25 | $26.0M | — | ||
| Q1 25 | $32.9M | — | ||
| Q4 24 | $31.9M | — | ||
| Q3 24 | $49.5M | — | ||
| Q2 24 | — | $373.4M | ||
| Q1 24 | — | $259.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $284.2K | $-48.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $284.2K | $-48.3M | ||
| Q3 25 | $-376.8K | $-36.2M | ||
| Q2 25 | $-1.9M | — | ||
| Q1 25 | $-178.4K | — | ||
| Q4 24 | $-4.2M | — | ||
| Q3 24 | $-243.5K | — | ||
| Q2 24 | — | $116.3M | ||
| Q1 24 | — | $-52.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-4.3M | — | ||
| Q3 24 | $-278.5K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -24.4% | — | ||
| Q3 24 | -1.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -2.97× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.36× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
